KALA BIO, Inc. short interest in 2024
In 2024, KALA BIO, Inc.'s disclosed short interest ran from 1.26% of shares outstanding on 12 Jan 2024 to 0.55% on 31 Dec 2024, a change of -0.71 percentage points. The year's high was 1.26% on 12 Jan 2024 and its low 0.18% on 15 Apr 2024, averaging 0.51% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 3.29 days on 15 Oct 2024. Full history: KALA BIO, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 1.26% (12 Jan 2024)
- End of year
- 0.55% (31 Dec 2024)
- Change
- -0.71 pp
- High
- 1.26% (12 Jan 2024)
- Low
- 0.18% (15 Apr 2024)
- Average
- 0.51%
- Highest days to cover
- 3.29 (15 Oct 2024)
- SEC filings marked
- 8
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 1.26% | 1.00 | |
| 31 Jan 2024 | 0.63% | 1.00 | |
| 15 Feb 2024 | 0.45% | 1.00 | |
| 29 Feb 2024 | 0.37% | 1.00 | |
| 15 Mar 2024 | 0.45% | 1.00 | |
| 28 Mar 2024 | 0.21% | 1.00 | |
| 15 Apr 2024 | 0.18% | 1.00 | 10-K filed, results (8-K) |
| 30 Apr 2024 | 0.31% | 1.04 | |
| 15 May 2024 | 0.21% | 1.00 | 10-Q filed, results (8-K) |
| 31 May 2024 | 0.27% | 1.00 | |
| 14 Jun 2024 | 0.48% | 1.00 | |
| 15 Aug 2024 | 0.68% | 1.39 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 0.49% | 3.15 | |
| 13 Sep 2024 | 0.47% | 2.58 | |
| 30 Sep 2024 | 0.65% | 1.85 | |
| 15 Oct 2024 | 0.64% | 3.29 | |
| 31 Oct 2024 | 0.81% | 1.27 | |
| 15 Nov 2024 | 0.66% | 1.00 | 10-Q filed, results (8-K) |
| 29 Nov 2024 | 0.57% | 1.00 | |
| 13 Dec 2024 | 0.47% | 1.00 | |
| 31 Dec 2024 | 0.55% | 1.05 |
See also: KALA BIO, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.